SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Charupong Saengboonmee, Wunchana Seubwai, Chaisiri Wongkham, Sopit Wongkham, Diabetes mellitus: Possible risk and promoting factors of cholangiocarcinoma, Cancer Epidemiology, 2015, 39, 3, 274

    CrossRef

  2. 2
    Qun Liang, Cong Wang, Binbing Li, Ai-hua Zhang, Lipidomics analysis based on liquid chromatography mass spectrometry for hepatocellular carcinoma and intrahepatic cholangiocarcinoma, RSC Adv., 2015, 5, 78, 63711

    CrossRef

  3. 3
    Dong Zhao, Xi-Dai Long, Tian-Fei Lu, Tao Wang, Wei-Wei Zhang, Yi-Xiao Liu, Xiao-Lan Cui, Hui-Juan Dai, Feng Xue, Qiang Xia, Metformin decreases IL-22 secretion to suppress tumor growth in an orthotopic mouse model of hepatocellular carcinoma, International Journal of Cancer, 2015, 136, 11
  4. 4
    Zhen Yang, Xiaodan Zhang, Rosebud O. Roberts, Lewis R. Roberts, Roongruedee Chaiteerakij, Metformin does not improve survival of cholangiocarcinoma in persons with diabetes, Hepatology, 2015, 62, 3
  5. 5
    Yen-Chun Peng, Cheng-Li Lin, Wan-Yun Hsu, Chi-Sen Chang, Hong-Zen Yeh, Chun-Fang Tung, Yuh-Lin Wu, Fung-Chang Sung, Chia-Hung Kao, Statins are associated with a reduced risk of cholangiocarcinoma: a population-based case–control study, British Journal of Clinical Pharmacology, 2015, 80, 3
  6. 6
    Ming-Shian Tsai, Po-Huang Lee, Cheng-Li Lin, Chiao-Ling Peng, Chia-Hung Kao, Type II diabetes mellitus is associated with a reduced risk of cholangiocarcinoma in patients with biliary tract diseases, International Journal of Cancer, 2015, 136, 10
  7. 7
    Nataliya Razumilava, Gregory J Gores, Cholangiocarcinoma, The Lancet, 2014, 383, 9935, 2168

    CrossRef

  8. 8
    Xiaodan Zhang, William S. Harmsen, Teresa A. Mettler, W. Ray Kim, Rosebud O. Roberts, Terry M. Therneau, Lewis R. Roberts, Roongruedee Chaiteerakij, Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of patients with diabetes, Hepatology, 2014, 60, 6
  9. 9
    Sudhakar K. Venkatesh, Vishal Chandan, Lewis R. Roberts, Liver Masses: A Clinical, Radiologic, and Pathologic Perspective, Clinical Gastroenterology and Hepatology, 2014, 12, 9, 1414

    CrossRef

  10. 10
    Jun-Shan Li, Tian-Jie Han, Nie Jing, Lei Li, Xiao-Hua Zhang, Feng-Zhen Ma, Ji-Yong Liu, Obesity and the risk of cholangiocarcinoma: a meta-analysis, Tumor Biology, 2014, 35, 7, 6831

    CrossRef

  11. 11
    M. Shi, H. Zheng, B. Nie, W. Gong, X. Cui, Statin use and risk of liver cancer: an update meta-analysis, BMJ Open, 2014, 4, 9, e005399

    CrossRef

  12. 12
    Tetsuji Fujita, Analyzing risk factors for intrahepatic cholangiocarcinoma, Hepatology, 2013, 58, 5
  13. 13
    I. Raz, Guideline Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes, Diabetes Care, 2013, 36, Supplement_2, S139

    CrossRef

  14. 14
    Laurent Sulpice, Michel Rayar, Mireille Desille, Bruno Turlin, Alain Fautrel, Eveline Boucher, Francisco Llamas-Gutierrez, Bernard Meunier, Karim Boudjema, Bruno Clément, Cédric Coulouarn, Molecular profiling of stroma identifies osteopontin as an independent predictor of poor prognosis in intrahepatic cholangiocarcinoma, Hepatology, 2013, 58, 6
  15. 15
    Emmanuel Beck, André J. Scheen, Quels bénéfices antitumoraux attendre de la metformine ?, Annales d'Endocrinologie, 2013, 74, 2, 137

    CrossRef